NanoAntibiotics, Inc. — Form 10-Q summary
Filing identity: The request metadata names BioVie Inc., but the filing identifies the registrant as NanoAntibiotics, Inc. The report covers the three months ended September 30, 2013; the company was incorporated April 10, 2013 and reports as a development-stage company. Financial statements are unaudited. The filing provides inception-to-date figures but no prior-year comparable quarter.
Business context
NanoAntibiotics is an early-stage biotechnology company pursuing broad-spectrum antibiotics for drug-resistant bacterial infections. It had no products for sale and no revenue. Its candidates had been tested only in cell-based assays; animal efficacy and toxicity studies had not yet been conducted. On October 3, 2013, after quarter-end, Kard Scientific and President Rajah Menon assigned related efflux-pump antibiotic rights, formulations, studies, and data to the company. The company recorded the rights at zero historical cost.
Financial results and position
| Metric | Three months ended September 30, 2013 | Inception through September 30, 2013 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $11,420 | $11,420 |
| Selling, general and administrative expense | $42,163 | $59,678 |
| Net loss | $53,493 | $71,003 |
| Operating cash used | $59,848 | $62,358 |
Gross margin was not meaningful because there were no sales or cost of goods sold. Basic and diluted loss per share was reported as $(0.00). Cash at September 30 was $445,848, down from $505,696 at June 30. Current liabilities consisted of $8,645 of accounts payable; the filing reports no debt. Stockholders’ equity was reported as $437,204 on the balance sheet, while the equity statement shows $437,203, a $1 discrepancy to verify. The company raised $508,206 from common-stock issuance from inception through June 30; no financing cash flow occurred in the quarter.
Changes, outlook, and risks
- Quarterly net loss was $53,493, compared with $17,510 from inception through June 30; the periods are not directly comparable. Quarterly cash used in operations was $59,848.
- Management estimated next-12-month spending of $500,000 for research and development, $100,000 for corporate overhead, $75,000 for capital costs, and $100,000 for staffing. It estimated that approximately $330,000 of additional net financing was needed to meet that budget.
- Management said existing cash was expected to fund operations only until March 31, 2014, and was insufficient for the next 12 months. It planned approximately $250,000 of lab studies for the quarter ending December 31, 2013, with possible additional study spending depending on results.
- The company intended to seek equity or debt financing, licensing, partnerships, or other transactions; there was no assurance of funding. Without funds, it could delay or reduce development, license programs, seek a business combination or sale, cease operations, or enter bankruptcy. The filing raises substantial doubt about its ability to continue as a going concern.
- Drug development is lengthy, costly, and subject to scientific, regulatory, financing, and commercial uncertainty. The company had limited pharmaceutical-development experience; budgets and timelines could change. FDA or equivalent approval would be required before sales.
- The company had engaged S&T Global for formulation and preclinical work on an hourly basis, without a material definitive written agreement; either party could terminate at any time. It reported $9,600 paid to the vendor for July through September work.
- Management concluded disclosure controls and procedures were ineffective as of September 30, 2013. No material change in internal control over financial reporting was reported during the quarter. No material legal proceedings were disclosed.
Important facts for investors to verify
- Resolve the mismatch between the requested company, BioVie Inc., and the filing registrant, NanoAntibiotics, Inc.; confirm that this is the intended filing and reporting period.
- Verify the reported $1 difference in September 30 stockholders’ equity and the assumptions underlying the estimated $330,000 financing need.
- Assess financing availability and runway beyond the stated March 31, 2014 estimate, including whether planned studies and spending were funded.
- Track preclinical progress, including whether candidates advance from cell-based assays to animal studies, and any subsequent regulatory or partnership developments.
- Review the October 3, 2013 rights transfer and the related-party relationship with Kard and Mr. Menon, including the basis for recording the transferred rights at zero cost.
- Review remediation of ineffective disclosure controls and any subsequent filings or updates to the going-concern assessment.